Keywords
Bisphosphonate
Osteoporosis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To correlate prolonged bisphosphonate use, for more than 3 years, as a risk factor for atypical femur fractures. Methods: This is an integrative literature review conducted using the descriptors “atypical femur fracture” and “bisphosphonate,” employing the Boolean operator “AND.” The databases used were the National Library of Medicine (PubMed), the Virtual Health Library (BVS), and the Cochrane Library. Articles were included based on the following criteria: published between 2013 and 2023, available in full text in Portuguese, English, or Spanish, and belonging to one of the following study types: clinical trials, controlled clinical trials, and observational studies. Results: The search and selection criteria yielded a total of 23 articles that associated bisphosphonate use with atypical femur fractures after a certain duration of treatment. Final Considerations: Bisphosphonate users should be evaluated after 3 years of use, considering the risk of atypical femur fractures and the need to individualize treatment continuation decisions to balance benefits and risks.
References
ADLER RA, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2016; 31(1): 16-35.
AGARWALA S, et al. Caveats of bisphosphonate abuse. Indian Journal of Orthopaedics, 2016; 50(4): 434-439.
ALWAHHABI BK e ALSUWANIE BA. Long-term use of bisphosphonates in osteoporosis. Saudi Med J, 2017; 38(6): 604-608.
BORGGAARD XG, et al. Alendronate prolongs the reversal-resorption phase in human cortical bone remodeling. Bone, 2022; 160: 116419.
BROWN JP, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician, 2014; 60(4): 324-333.
BROWN JP. Antiresorptives: Safety Concerns - Clinical Perspective. Toxicologic Pathology, 2017; 45(7): 859-863.
CANBEK U, et al. Incomplete atypical femoral fractures after bisphosphonate use in postmenopausal women. Journal of Orthopaedic Surgery, 2019; 27(3): 230949901987526.
FALOTICO GG, et al. Fraturas atípicas do fêmur associadas ao uso atual de bisfosfonatos: uma série de casos de 66 pacientes. Revista Brasileira de Ortopedia, 2022; 57(5): 851-855.
FAVINGER JL, et al. Long-term radiographic follow-up of bisphosphonate-associated atypical femur fractures. Skeletal Radiol, 2016; 627-33.
FINK HA, et al. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Ann Intern Med, 2019; 171(1): 37-50.
GARGYÁN I, et al. Bisphosphonate therapy associated with bilateral atypical femoral fracture and delayed union. Jt Dis Relat Surg, 2022; 33(1): 24-32.
GREENSAPAN SL, et al. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. Osteoporosis International, 2018; 29(2): 501-506.
GU KD, et al. Progressão de fratura de estresse atípica do fêmur após descontinuação da terapia com bifosfonatos. Osteoporosis International, 2021; 32(10): 2119-2123.
HAGINO H, et al. Treatment status and radiographic features of patients with atypical femoral fractures. J Orthop Sci, 2018; 23(2): 316-320.
HWANG S, et al. Bilateral Atypical Femoral Fractures after Bisphosphonate Treatment for Osteoporosis: A Literature Review. Journal of Clinical Medicine, 2023; 12(3): 1038-1057.
ISHTIAQ S, et al. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine, 2015; 71(2): 154-160.
LEE S, et al. Increased risk for atypical fractures associated with bisphosphonate use. Family Practice, 2015; 32(3): 276-281.
LEE SH, et al. Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea. J Bone Metab, 2015; 22(4): 167-174.
LEE YK, et al. Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea. J Korean Med Sci, 2018; 33(5): 38.
LO JC, et al. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord, 2020; 21(1): 801.
MAHJOUB Z, et al. Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data. J Bone Miner Res. 2016; 31(4): 767-776.
NEDER YV, et al. Fracturas atípicas de fémur proximal asociadas al uso prolongado de bifosfonatos. Revista de la Asociación Argentina de Ortopedia y Traumatología, 2018; 83(3): 152-156.
PAZIANAS M, et al. Questioning the association between bisphosphonates and atypical femoral fractures. Annals of the New York Academy of Sciences, 2014; 1335(1): 1-9.
POPP KL, et al. Cortical Bone Material Strength Index and Bone Microarchitecture in Postmenopausal Women With Atypical Femoral Fractures. Journal of Bone and Mineral Research, 2019; 34(1): 75-82.
SOZEN T, et al. An overview and management of osteoporosis. European Journal of Rheumatology, 2017; 4(1): 46-56.
TEMPOSNI EF, et al. Fratura femoral atípica devido ao uso corrente de bifosfonato. Relato do caso. Revista Brasileira de Ortopedia, 2015; 50(4): 482-485.
TILE L e CHEUNG AM. Atypical femur fractures: current understanding and approach to management. Therapeutic Advances in Musculoskeletal Disease, 2020; 12: 1759720X20916983.
VAN BAARSEL ED, et al. Atypical femoral fracture in the setting of alendronate treatment for osteoporosis: a case report and literature review. Journal of Community Hospital Internal Medicine Perspectives, 2019; 9(4): 340-343.
VAN DE LAARSCHOT DM, et al. Screening for Atypical Femur Fractures Using Extended Femur Scans by DXA. Journal of Bone and Mineral Research, 2017; 32(8): 1632-1639.
VINCENZO G, et al. Fraturas femorais atípicas por uso prolongado de bifosfonatos: mitos e verdades. J bras med, 2013; 101(2): 13-18.
WANG M, et al. Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real‐World Studies. JBMR Plus, 2022; 6(6): 1-17.